GSK, Vir's hopes for a Covid-19 antibody fall flat in NIH 'master protocol' with no benefit in hospitalized patients

Kyle Blankenship

GlaxoSmithKline and Vir Biotechnology were hopeful that one of their partnered antibodies would carve out a win after getting the invite to a major NIH …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GSK, Vir's hopes for a Covid-19 antibody fall flat in NIH 'master protocol' with no benefit in hospitalized patients

Kyle Blankenship

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

Gilead buys experimental HIV vaccines from a small Barcelona biotech

GSK, Vir's hopes for a Covid-19 an­ti­body fall flat in NIH 'mas­ter pro­to­col' with no ben­e­fit in hos­pi­tal­ized pa­tients

Kyle Blankenship

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

GSK, Vir's hopes for a Covid-19 antibody fall flat in NIH 'master protocol' with no benefit in hospitalized patients

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

Gilead buys experimental HIV vaccines from a small Barcelona biotech